冠状病毒和 SARS-CoV-2：简要概述。
Coronaviruses and SARS-CoV-2: A Brief Overview.
机构信息
From the Institute of Molecular Virology (IMV), University Hospital Münster, Münster, Germany.
Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Munster, Germany.
出版信息
Anesth Analg. 2020 Jul;131(1):93-96. doi: 10.1213/ANE.0000000000004845.
Abstract
In late December 2019, several cases of pneumonia of unknown origin were reported from China, which in early January 2020 were announced to be caused by a novel coronavirus. The virus was later denominated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and defined as the causal agent of coronavirus disease 2019 (COVID-19). Despite massive attempts to contain the disease in China, the virus has spread globally, and COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020. Here we provide a short background on coronaviruses, and describe in more detail the novel SARS-CoV-2 and attempts to identify effective therapies against COVID-19.
摘要
2019 年 12 月下旬，中国报告了几例不明原因的肺炎病例，这些病例在 2020 年 1 月初被宣布是由一种新型冠状病毒引起的。该病毒后来被命名为严重急性呼吸综合征冠状病毒 2（SARS-CoV-2），并被定义为 2019 年冠状病毒病（COVID-19）的病原体。尽管中国采取了大规模措施来控制这种疾病，但该病毒已在全球范围内传播，世界卫生组织（WHO）于 2020 年 3 月宣布 COVID-19 为大流行。在这里，我们提供了有关冠状病毒的简要背景，并更详细地描述了新型 SARS-CoV-2 以及试图确定针对 COVID-19 的有效疗法的情况。
相似文献
1
Coronaviruses and SARS-CoV-2: A Brief Overview.冠状病毒和 SARS-CoV-2：简要概述。
Anesth Analg. 2020 Jul;131(1):93-96. doi: 10.1213/ANE.0000000000004845.
2
The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.新型严重急性呼吸系统综合症冠状病毒 2（SARS-CoV-2）的爆发：当前全球状况综述。
J Infect Public Health. 2020 Nov;13(11):1601-1610. doi: 10.1016/j.jiph.2020.07.011. Epub 2020 Aug 4.
3
Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19).关于 19 冠状病毒病（COVID-19）的遗传学、进化、免疫发病机制和传播的最新知识更新。
Int J Biol Sci. 2020 Sep 12;16(15):2906-2923. doi: 10.7150/ijbs.48812. eCollection 2020.
4
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情：一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
5
From SARS to COVID-19: What lessons have we learned?从 SARS 到 COVID-19：我们从中吸取了哪些教训？
J Infect Public Health. 2020 Nov;13(11):1611-1618. doi: 10.1016/j.jiph.2020.08.001. Epub 2020 Aug 21.
6
[Characteristics of SARS-CoV-2 and potential pharmacological treatment].[严重急性呼吸综合征冠状病毒2的特征及潜在药物治疗]
Postepy Biochem. 2020 May 9;66(2):83-90. doi: 10.18388/pb.2020_321.
7
Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China.中国严重急性呼吸综合征冠状病毒 2 不存在垂直传播。
Emerg Infect Dis. 2020 Jun;26(6):1335-1336. doi: 10.3201/eid2606.200287. Epub 2020 Jun 17.
8
Audio Interview: Caring for Patients with Covid-19.音频访谈：照顾新冠病毒肺炎患者
N Engl J Med. 2020 Apr 16;382(16):e50. doi: 10.1056/NEJMe2011242.
9
COVID-19 diagnosis and management: a comprehensive review.COVID-19 的诊断与管理：全面综述。
J Intern Med. 2020 Aug;288(2):192-206. doi: 10.1111/joim.13091. Epub 2020 May 13.
10
SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.SARS-CoV-2 跨越物种屏障：SARS、MERS 带来的人畜共患病教训及应对此次大流行病毒的最新进展。
Travel Med Infect Dis. 2020 Sep-Oct;37:101830. doi: 10.1016/j.tmaid.2020.101830. Epub 2020 Aug 2.
引用本文的文献
1
Gut microbiota and viral respiratory infections: microbial alterations, immune modulation, and impact on disease severity: a narrative review.肠道微生物群与病毒性呼吸道感染：微生物变化、免疫调节及对疾病严重程度的影响：一项叙述性综述
Front Microbiol. 2025 Jul 18;16:1605143. doi: 10.3389/fmicb.2025.1605143. eCollection 2025.
2
Identification of HIF1A as a therapeutic target during SARS-CoV-2-associated lung injury.鉴定缺氧诱导因子1α（HIF1A）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）相关肺损伤期间的治疗靶点。
JCI Insight. 2025 Jun 17;10(14). doi: 10.1172/jci.insight.191463. eCollection 2025 Jul 22.
3
Understanding the Mental Health of Students and Professors within Universities: a Cross-sectional, Multicultural Analysis across Three European Countries.了解大学内学生和教授的心理健康：一项对三个欧洲国家的横断面多元文化分析。
Invest Educ Enferm. 2025 Apr;43(1). doi: 10.17533/udea.iee.v43n1e08.
4
Structural and Phylogenetic Analysis on the Proofreading Activity of SARS-CoV-2.新型冠状病毒（SARS-CoV-2）校对活性的结构与系统发育分析
Curr Microbiol. 2025 Feb 24;82(4):149. doi: 10.1007/s00284-025-04130-3.
5
Globally approved vaccines for COVID-19: a systematic review.全球批准的新冠病毒疫苗：一项系统综述。
Braz J Microbiol. 2025 Mar;56(1):511-527. doi: 10.1007/s42770-024-01600-x. Epub 2025 Jan 9.
6
Clinical, biochemical, and genetic study of TACE/TNF-α/ACE signaling pathway in pediatric COVID-19 infection.儿童新型冠状病毒肺炎感染中TACE/TNF-α/ACE信号通路的临床、生化及遗传学研究
Clin Exp Pediatr. 2024 Dec;67(12):704-717. doi: 10.3345/cep.2024.00941. Epub 2024 Nov 27.
7
Antiviral Effects and Mechanisms of Active Ingredients in Tea.茶中活性成分的抗病毒作用及机制。
Molecules. 2024 Nov 4;29(21):5218. doi: 10.3390/molecules29215218.
8
Depression, Anxiety and Associated Factors Among Korean Adolescent Students During COVID-19.新冠疫情期间韩国青少年学生的抑郁、焦虑及相关因素
J Korean Acad Child Adolesc Psychiatry. 2024 Oct 1;35(4):230-242. doi: 10.5765/jkacap.220039.
9
A potential allosteric inhibitor of SARS-CoV-2 main protease (M) identified through metastable state analysis.通过亚稳态分析鉴定出的一种潜在的严重急性呼吸综合征冠状病毒2型主要蛋白酶（M）变构抑制剂。
Front Mol Biosci. 2024 Sep 6;11:1451280. doi: 10.3389/fmolb.2024.1451280. eCollection 2024.
10
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.新型冠状病毒肺炎（COVID-19）的全面综述：流行病学、发病机制、诊断和检测技术的进展，以及大流行后的治疗策略。
Int J Mol Sci. 2024 Jul 26;25(15):8155. doi: 10.3390/ijms25158155.
本文引用的文献
1
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
Management of Critically Ill Adults With COVID-19.新型冠状病毒肺炎危重症成人患者的管理
JAMA. 2020 May 12;323(18):1839-1841. doi: 10.1001/jama.2020.4914.
3
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
4
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
5
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.
6
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.抗病毒化合物瑞德西韦能有效抑制中东呼吸综合征冠状病毒的 RNA 依赖性 RNA 聚合酶。
J Biol Chem. 2020 Apr 10;295(15):4773-4779. doi: 10.1074/jbc.AC120.013056. Epub 2020 Feb 24.
7
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.中国2019年冠状病毒病（COVID-19）疫情的特征及重要经验教训：来自中国疾病预防控制中心72314例病例报告的总结
JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.
8
Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes.2019-nCoV 感染患者的分子和血清学调查：多种脱落途径的意义。
Emerg Microbes Infect. 2020 Feb 17;9(1):386-389. doi: 10.1080/22221751.2020.1729071. eCollection 2020.
9
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.预防性和治疗性瑞德西韦（GS-5734）治疗中东呼吸综合征冠状病毒感染恒河猴模型。
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776. doi: 10.1073/pnas.1922083117. Epub 2020 Feb 13.
10
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.《武汉 2019 年新型冠状病毒感染的肺炎 138 例住院患者临床特征分析》
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
Zotero 插件